司美格鲁肽等GLP-1药物写入WHO全球指南用于肥胖症治疗

Core Viewpoint - The World Health Organization (WHO) has released its first global guidelines for the use of GLP-1 receptor agonists in obesity treatment, highlighting the urgent need to address the global obesity crisis, which affects over 1 billion people and is projected to double by 2030 [1][2] Group 1: Obesity and Health Impact - Obesity is defined by the WHO as having a Body Mass Index (BMI) of 30 or higher, and it is a chronic, relapsing disease that significantly contributes to non-communicable diseases such as cardiovascular diseases, type 2 diabetes, and certain cancers [1][2] - The number of deaths related to obesity is projected to reach 3.7 million in 2024, emphasizing the critical health challenge posed by this condition [1] Group 2: GLP-1 Drugs and Treatment Guidelines - The new guidelines recommend GLP-1 drugs, including semaglutide, as part of a comprehensive management plan for obesity, which should also include healthy diet, regular exercise, and professional health guidance [2] - GLP-1 receptor agonists are recognized for their ability to lower blood sugar, aid in weight loss, and reduce the risk of complications in type 2 diabetes patients, marking a shift from lifestyle-only interventions to more structured medical management [2] Group 3: Economic and Market Implications - The inclusion of GLP-1 drugs in the WHO's Essential Medicines List for managing type 2 diabetes in high-risk populations indicates their growing importance in global chronic disease management [2] - The innovative GLP-1 drugs are expected to have a profound impact on public health and healthcare expenditure, similar to the effects of statins, as the related industry chain and market size continue to expand [2]